Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study

References

• Chen Z, Zhang W, Chen X, et al. Trends in end-stage kidney disease in Shanghai, China. Kidney Int. 2019;95(1):232.
   PubMed Web of Science ®Google Scholar
• Annual Data Reports of USRDS; 2019 [cited 2020 Mar 9]. Available from: https://www.usrds.org/2019/view/Default.aspx.
   Google Scholar
• Kurella Tamura M, Thomas IC, Montez-Rath ME, et al. Dialysis initiation and mortality among older veterans with kidney failure treated in medicare vs the Department of Veterans Affairs. JAMA Intern Med. 2018;178(5):657–664.
   PubMed Web of Science ®Google Scholar
• Madsen LH, Ladefoged S, Corell P, et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007;71(6):548–554.
   PubMed Web of Science ®Google Scholar
• Chen YH, Fu YC, Wu MJ. NT-ProBNP predicts total mortality, emergency department visits, hospitalization, intensive-care unit admission, and cardiovascular events in hemodialysis patients. J Clin Med. 2019;8(2):238.
   Google Scholar
• Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012;52(1–2):89–99.
   PubMed Web of Science ®Google Scholar
• Obokata M, Sunaga H, Ishida H, et al. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients. Am Heart J. 2016;179:29–41.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Shen B, Cao X, et al. Increased soluble suppression of tumorigenicity 2 level predicts all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. Blood Purif. 2017;43(1–3):37–45.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.
   PubMed Web of Science ®Google Scholar
• Obokata M, Kurosawa K, Ishida H, et al. Incremental prognostic value of ventricular-arterial coupling over ejection fraction in patients with maintenance hemodialysis. J Am Soc Echocardiogr. 2017;30(5):444–453.e442.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang C, Zhuang R, et al. IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells. PLoS Negl Trop Dis. 2015;9(2):e0003514.
   PubMed Web of Science ®Google Scholar
• Bao YS, Na SP, Zhang P, et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 2012;32(3):587–594.
   PubMed Web of Science ®Google Scholar
• Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Morrow DA, Cannon CP, et al. Multimarker risk stratification in patients with acute myocardial infarction. JAHA. 2016;5(5):e002586.
   Google Scholar
• Parikh RH, Seliger SL, Christenson R, et al. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. JAHA. 2016;5(8):e003188.
   Google Scholar
• AbouEzzeddine OF, McKie PM, Dunlay SM, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. JAHA. 2017;6(2):e004382.
   Google Scholar
• Xanthakis V, Larson MG, Wollert KC, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013;2(6):e000399.
   PubMed Web of Science ®Google Scholar
• Gungor O, Unal HU, Guclu A, et al. IL-33 and ST2 levels in chronic kidney disease: associations with inflammation, vascular abnormalities, cardiovascular events, and survival. PLOS One. 2017;12(6):e0178939.
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648–658.
   PubMed Web of Science ®Google Scholar
• Wang YC, Yu CC, Chiu FC, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Cardiac Fail. 2013;19(3):163–168.
   PubMed Web of Science ®Google Scholar
• Yu J, Oh PC, Kim M, et al. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLOS One. 2017;12(8):e0182829.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Di Somma S, Maisel AS, et al. Bayes-Genis A. ST2 and multimarker testing in acute decompensated heart failure. Am J Cardiol. 2015;115(7 Suppl):38B–43b.
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Januzzi JL, Jr., Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma – the Presage ST2 assay. Clin Chim Acta. 2009;409(1–2):33–40.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Zamora E, de Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure. J Cardiac Fail. 2013;19(11):768–775.
   PubMed Web of Science ®Google Scholar
• Meijers WC, van der Velde AR, Ruifrok WP, et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc. 2014;3(5):e000962.
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164(2):277–281.
   PubMed Web of Science ®Google Scholar